Tissue damage and immunity in cutaneous leishmaniasis

Parasite Immunology

Volumn 34, Issue 12, 2012, Pages 551-561

  Nylen S ^a   Eidsmo, L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chronic infectious ulcers; Cutaneous leishmaniasis; Tissue pathology

Indexed keywords

ANTIMONY; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 27; RECOMBINANT INTERLEUKIN 12; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; EXPERIMENTAL MODEL; GENETIC ENGINEERING; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOPATHOLOGY; INFECTION RISK; INFLAMMATION; INFLAMMATORY INFILTRATE; LEISHMANIA; LEISHMANIA AETHIOPICA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LYMPHATIC DRAINAGE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN LEISHMANIASIS; SKIN ULCER; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TISSUE INJURY; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MICE; SKIN;

ANIMALIA; MUS;

EID: 84870190681     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12007     Document Type: Review

References (108)

1. Nestle FO, Di Meglio P, Qin JZ & Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9: 679-691.
2. Merad M, Ginhoux F & Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8: 935-947.
3. Seneschal J, Clark RA, Gehad A, Baecher-Allan CM & Kupper TS. Human epidermal langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 2012; 36: 873-884.
4. Heath WR & Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10: 1237-1244.
5. Teunissen MB, Haniffa M & Collin MP. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr Top Microbiol Immunol 2012; 351: 25-76.
6. Bailey MS & Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol 2007; 25: 203-211.
7. Ridley DS, Marsden PD, Cuba CC & Barreto AC. A histological classification of mucocutaneous leishmaniasis in Brazil and its clinical evaluation. Trans R Soc Trop Med Hyg 1980; 74: 508-514.
8. Gaafar A, el Kadaro AY, Theander TG, et al. The pathology of cutaneous leishmaniasis due to Leishmania major in Sudan. Am J Trop Med Hyg 1995; 52: 438-442.
9. Ridley MJ & Ridley DS. Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase. Br J Exp Pathol 1984; 65: 327-336.
10. Aronson NE, Wortmann GW, Byrne WR, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Negl Trop Dis 2010; 4: e628.
11. Lopez L, Robayo M, Vargas M & Velez I. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13: 58.
12. Laskay T, van Zandbergen G & Solbach W. Neutrophil granulocytes as host cells and transport vehicles for intracellular pathogens: apoptosis as infection-promoting factor. Immunobiology 2008; 213: 183-191.
13. Peters NC, Egen JG, Secundino N, et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008; 321: 970-974.
14. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129: 447-450.
15. Ribeiro-Gomes FL, Otero AC, Gomes NA, et al. Macrophage interactions with neutrophils regulate Leishmania major infection. J Immunol 2004; 172: 4454-4462.
16. van Zandbergen G, Klinger M, Mueller A, et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol 2004; 173: 6521-6525.
17. Ehrchen JM, Roebrock K, Foell D, et al. Keratinocytes determine Th1 immunity during early experimental leishmaniasis. PLoS Pathog 2010; 6: e1000871.
18. Kim BS, Miyagawa F, Cho YH, Bennett CL, Clausen BE & Katz SI. Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis. J Invest Dermatol 2009; 129: 2805-2817.
19. Basham TY, Nickoloff BJ, Merigan TC & Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984; 83: 88-90.
20. Sakthianandeswaren A, Elso CM, Simpson K, et al. The wound repair response controls outcome to cutaneous leishmaniasis. Proc Natl Acad Sci USA 2005; 102: 15551-15556.
21. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G & Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165: 969-977.
22. Kumar R, Bumb RA & Salotra P. Correlation of parasitic load with interleukin-4 response in patients with cutaneous leishmaniasis due to Leishmania tropica. FEMS Immunol Med Microbiol 2009; 57: 239-246.
23. Naik S, Bouladoux N, Wilhelm C, et al. Compartmentalized Control of Skin Immunity by Resident Commensals. Science 2012; 337: 1115-1119.
24. Belkaid Y, Hoffmann KF, Mendez S, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194: 1497-1506.
25. Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M & Barral A. Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am J Trop Med Hyg 2007; 77: 854-859.
26. Boaventura VS, Santos CS, Cardoso CR, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40: 2830-2836.
27. Safaiyan S, Bolhassani A, Nylen S, Akuffo H & Rafati S. Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection. Parasite Immunol 2011; 33: 609-620.
28. Baldwin T, Sakthianandeswaren A, Curtis JM, et al. Wound healing response is a major contributor to the severity of cutaneous leishmaniasis in the ear model of infection. Parasite Immunol 2007; 29: 501-513.
29. Vaalamo M, Kariniemi AL, Shapiro SD & Saarialho-Kere U. Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. J Invest Dermatol 1999; 112: 499-505.
30. Sakthianandeswaren A, Curtis JM, Elso C, et al. Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing. Infect Immun 2010; 78: 2734-2744.
31. Sharifi I, Fekri AR, Aflatoonian MR, et al. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Int J Dermatol 2010; 49: 557-561.
32. Belkaid Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-1953.
33. Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans R Soc Trop Med Hyg 1969; 63: 708-737.
34. Shirian S, Oryan A, Hatam GR, Daneshbod K & Daneshbod Y. Molecular diagnosis and species identification of mucosal leishmaniasis in Iran and correlation with cytological findings. Acta Cytol 2012; 56: 304-309.
35. Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG & D'Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg 1987; 36: 489-496.
36. Manzur A & Bari A. Sensitivity of leishmanin skin test in patients of acute cutaneous leishmaniasis. Dermatol Online J 2006; 12: 2.
37. Sadeghian G, Momeni A, Siadat AH & Yousefi P. Evaluation of leishmanin skin test and its relationship with the clinical form and duration of cutaneous leishmaniasis. Dermatol Online J 2006; 12: 3.
38. Silveira FT, Blackwell JM, Ishikawa EA, et al. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 1998; 20: 19-26.
39. Petersen EA, Neva FA, Barral A, et al. Monocyte suppression of antigen-specific lymphocyte responses in diffuse cutaneous leishmaniasis patients from the Dominican Republic. J Immunol 1984; 132: 2603-2606.
40. Sinha S, Fernandez G, Kapila R, Lambert WC & Schwartz RA. Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 2008; 47: 1263-1270.
41. Esterre P, Dedet JP, Frenay C, Chevallier M & Grimaud JA. Cell populations in the lesion of human cutaneous leishmaniasis: a light microscopical, immunohistochemical and ultrastructural study. Virchows Arch A Pathol Anat Histopathol 1992; 421: 239-247.
42. Modlin RL, Pirmez C, Hofman FM, et al. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989; 339: 544-548.
43. Lima HC, Vasconcelos AW, David JR & Lerner EA. American cutaneous leishmaniasis: in situ characterization of the cellular immune response with time. Am J Trop Med Hyg 1994; 50: 743-747.
44. Sotto MN, Halpern I, Kauffman MR & Pagliari C. Factor XIIIa+ dermal dendrocyte parasitism in American tegumentary leishmaniasis skin lesions. Am J Dermatopathol 2010; 32: 15-18.
45. McLachlan JB, Catron DM, Moon JJ & Jenkins MK. Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 2009; 30: 277-288.
46. Leon B, Lopez-Bravo M & Ardavin C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 2007; 26: 519-531.
47. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL & Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
48. Sacks D & Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858.
49. Anderson CF, Lira R, Kamhawi S, Belkaid Y, Wynn TA & Sacks D. IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol 2008; 180: 4090-4097.
50. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM & Sacks DL. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-507.
51. Katara GK, Ansari NA, Verma S, Ramesh V & Salotra P. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis 2011; 5: e1171.
52. Saha S, Mondal S, Ravindran R, et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 2007; 179: 5592-5603.
53. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ & Srimal S. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990; 145: 940-944.
54. Dunham DM, Arkins S, Edwards CK III, Dantzer R & Kelley KW. Role of interferon-gamma in counteracting the suppressive effects of transforming growth factor-beta 2 and glucocorticoids on the production of tumor necrosis factor-alpha. J Leukoc Biol 1990; 48: 473-481.
55. Reed SG. TGF-beta in infections and infectious diseases. Microbes Infect 1999; 1: 1313-1325.
56. Campanelli AP, Roselino AM, Cavassani KA, et al. CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 2006; 193: 1313-1322.
57. Da Silva SA, Costa SS, Mendonca SC, Silva EM, Moraes VL & Rossi-Bergmann B. Therapeutic effect of oral Kalanchoe pinnata leaf extract in murine leishmaniasis. Acta Trop 1995; 60: 201-210.
58. Carneiro FP, De Magalhaes AV, De Jesus Abreu Almeida Couto M, Bocca AL, Muniz-Junqueira MI & Ribeiro Sampaio RN. Foxp3 expression in lesions of the different clinical forms of American tegumentary leishmaniasis. Parasite Immunol 2009; 31: 646-651.
59. Kautz-Neu K, Noordegraaf M, Dinges S, et al. Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 2011; 208: 885-891.
60. Caceres-Dittmar G, Sanchez MA, Oriol O, Kraal G & Tapia FJ. Epidermal compromise in American cutaneous leishmaniasis. J Invest Dermatol 1992; 99: 95S-98S.
61. Ismail A, Gadir AF, Theander TG, Kharazmi A & El Hassan AM. Pathology of post-kala-azar dermal leishmaniasis: a light microscopical, immunohistochemical, and ultrastructural study of skin lesions and draining lymph nodes. J Cutan Pathol 2006; 33: 778-787.
62. Castes M & Tapia FJ. [Immunopathology of American tegumentary leishmaniasis]. Acta Cient Venez 1998; 49: 42-56.
63. Nogueira MF, Sotto MN & Cuce LC. American tegumentary leishmaniasis: Langerhans cells in Montenegro skin test. Rev Inst Med Trop Sao Paulo 2008; 50: 283-286.
64. Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5: e14108.
65. Anderson CF, Stumhofer JS, Hunter CA & Sacks D. IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 2009; 183: 4619-4627.
66. Belkaid Y, Von Stebut E, Mendez S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168: 3992-4000.
67. Brodskyn CI, Barral A, Boaventura V, Carvalho E & Barral-Netto M. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J Immunol 1997; 159: 4467-4473.
68. Faria DR, Souza PE, Duraes FV, et al. Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol 2009; 31: 432-439.
69. Ganguly S, Mukhopadhyay D, Das NK, et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. J Invest Dermatol 2010; 130: 1013-1022.
70. Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S & Bakhiet M. Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 1997; 175: 737-741.
71. Akuffo H, Schurr E, Andersson G, Yamaneberhan T & Britton S. Responsiveness in diffuse versus local cutaneous leishmaniasis is due to parasite differences. Scand J Immunol 1987; 26: 717-721.
72. Akuffo HO, Fehniger TE & Britton S. Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. J Immunol 1988; 141: 2461-2466.
73. Lemma A, Foster WA, Gemetchu T, Preston PM, Bryceson A & Minter DM. Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. Ann Trop Med Parasitol 1969; 63: 455-472.
74. Scott P, Natovitz P & Sher A. B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis. J Immunol 1986; 137: 1017-1021.
75. Ronet C, Hauyon-La Torre Y, Revaz-Breton M, et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol 2010; 184: 886-894.
76. Ronet C, Voigt H, Himmelrich H, et al. Leishmania major-specific B cells are necessary for Th2 cell development and susceptibility to L. major LV39 in BALB/c mice. J Immunol 2008; 180: 4825-4835.
77. Babai B, Louzir H, Cazenave PA & Dellagi K. Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice. Clin Exp Immunol 1999; 117: 123-129.
78. Brown DR & Reiner SL. Polarized helper-T-cell responses against Leishmania major in the absence of B cells. Infect Immun 1999; 67: 266-270.
79. Buxbaum LU & Scott P. Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun 2005; 73: 2101-2108.
80. Soong L. Modulation of dendritic cell function by Leishmania parasites. J Immunol 2008; 180: 4355-4360.
81. Kane MM & Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166: 1141-1147.
82. Mengistu G, Akuffo HO, Yemane-Berhan T, Britton S & Fehniger TE. Serum antibody specificities to Leishmania aethiopica antigens in patients with localized and diffuse cutaneous leishmaniasis. Parasite Immunol 1990; 12: 495-507.
83. Valli LC, Passos VM, Dietze R, Callahan HL, Berman JD & Grogl M. Humoral immune responses among mucosal and cutaneous leishmaniasis patients caused by Leishmania braziliensis. J Parasitol 1999; 85: 1076-1083.
84. Vieira MG, Oliveira F, Arruda S, et al. B-cell infiltration and frequency of cytokine producing cells differ between localized and disseminated human cutaneous leishmaniases. Mem Inst Oswaldo Cruz 2002; 97: 979-983.
85. Rethi B & Eidsmo L. FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control. Front Immunol 2012; 3: 163.
86. Eidsmo L, Fluur C, Rethi B, et al. FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major. Am J Pathol 2007; 170: 227-239.
87. Eidsmo L, Nylen S, Khamesipour A, Hedblad MA, Chiodi F & Akuffo H. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am J Pathol 2005; 166: 1099-1108.
88. Tasew G, Nylen S, Lieke T, et al. Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl Trop Dis 2010; 4: e844.
89. Boehncke WH, Prinz J & Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006; 33: 1447-1451.
90. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145-154.e149.
91. Hakimi S, Riviere S, Del Giudice P, Dereure J & Le Quellec A. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab. Dermatology 2010; 220: 63-65.
92. Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR & Loscher T. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009; 81: 52-54.
93. Li J, Hunter CA & Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 1999; 162: 974-979.
94. Nabors GS, Afonso LC, Farrell JP & Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci USA 1995; 92: 3142-3146.
95. Li J, Sutterwala S & Farrell JP. Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production. Infect Immun 1997; 65: 3225-3230.
96. Car BD, Eng VM, Lipman JM & Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999; 27: 58-63.
97. Akuffo H, Kaplan G, Kiessling R, et al. Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis. J Infect Dis 1990; 161: 775-780.
98. Divanovic S, Trompette A, Ashworth JI, Rao MB & Karp CL. Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis 2011; 5: e1316.
99. Kolde G, Luger T, Sorg C & Sunderkotter C. Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Dermatology 1996; 192: 56-60.
100. Falcoff E, Gimenez LA, Bernabo JG & Bottasso O. [Interferon gamma as an immunological strategy for the treatment of human leishmaniasis]. Medicina (B Aires) 1994; 54: 265-271.
101. Lee JY, Atochina O, King B, et al. Beryllium, an adjuvant that promotes gamma interferon production. Infect Immun 2000; 68: 4032-4039.
102. Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1970; 64: 380-393.
103. Nilsen R & Mshana RN. In situ characterization of the cutaneous immune response in Ethiopian cutaneous leishmaniasis. Scand J Immunol 1987; 26: 503-512.
104. Bacellar O, Lessa H, Schriefer A, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002; 70: 6734-6740.
105. Ruiz JH & Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 2007; 29: 671-678.
106. Ghosh MK, Nandy A, Addy M, Maitra TK & Ghose AC. Subpopulations of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients. Scand J Immunol 1995; 41: 11-17.
107. Rathi SK, Pandhi RK, Chopra P & Khanna N. Lesional T-cell subset in post-kala-azar dermal leishmaniasis. Int J Dermatol 2005; 44: 12-13.
108. Ridley DS & Ridley MJ. The evolution of the lesion in cutaneous leishmaniasis. J Pathol 1983; 141: 83-96.